Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Carcinogenesis
|
January 10, 2014
Integrin α6A splice variant regulates proliferation and the Wnt/β-catenin pathway in human colorectal cancer cells
Jean-François Groulx, Véronique Giroux, Marco Beauséjour, et al.
Molecular Cancer Therapeutics
|
November 20, 2025
Involvement of the FGF8/FGF receptor signaling pathway in the maintenance and progression of fusion-positive rhabdomyosarcoma
Salah Boudjadi, Hana Kim, Bishwanath Chatterjee, et al.
The Journal of Clinical Investigation
|
June 24, 2021
Serine hydroxymethyltransferase 2 expression promotes tumorigenesis in rhabdomyosarcoma with 12q13-q14 amplification
Thanh H Nguyen, Prasantha L Vemu, Gregory E Hoy, et al.
Current Opinion in Oncology
|
March 20, 2025
Antibody-drug conjugates in rare genitourinary tumors: review and perspectives
Andre R Kydd, Md Shahid Sarwar, Saad Atiq, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
August 22, 2025
Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management
Nicholas I Simon, Andre R Kydd, Dilara Akbulut, et al.
Future Oncology (London, England)
|
March 21, 2025
A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationale
Nicholas Simon, Elias Chandran, Saad Atiq, et al.
Future Oncology (London, England)
|
May 27, 2025
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale
Elias B A Chandran, Saad Atiq, Nicholas Simon, et al.
BMJ Oncology
|
August 1, 2024
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis
Elias B A Chandran, Giovanni Maria Iannantuono, Saad O Atiq, et al.
Future Oncology (London, England)
|
June 23, 2025
A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationale
Andre R Kydd, Elias Chandran, Nicholas I Simon, et al.
Biorxiv : the Preprint Server for Biology
|
August 1, 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology
Sumit Mukherjee, Sumeet Patiyal, Lipika R Pal, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Carcinogenesis
|
January 10, 2014
Integrin α6A splice variant regulates proliferation and the Wnt/β-catenin pathway in human colorectal cancer cells
Jean-François Groulx, Véronique Giroux, Marco Beauséjour, et al.
Molecular Cancer Therapeutics
|
November 20, 2025
Involvement of the FGF8/FGF receptor signaling pathway in the maintenance and progression of fusion-positive rhabdomyosarcoma
Salah Boudjadi, Hana Kim, Bishwanath Chatterjee, et al.
The Journal of Clinical Investigation
|
June 24, 2021
Serine hydroxymethyltransferase 2 expression promotes tumorigenesis in rhabdomyosarcoma with 12q13-q14 amplification
Thanh H Nguyen, Prasantha L Vemu, Gregory E Hoy, et al.
Current Opinion in Oncology
|
March 20, 2025
Antibody-drug conjugates in rare genitourinary tumors: review and perspectives
Andre R Kydd, Md Shahid Sarwar, Saad Atiq, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
August 22, 2025
Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management
Nicholas I Simon, Andre R Kydd, Dilara Akbulut, et al.
Future Oncology (London, England)
|
March 21, 2025
A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationale
Nicholas Simon, Elias Chandran, Saad Atiq, et al.
Future Oncology (London, England)
|
May 27, 2025
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale
Elias B A Chandran, Saad Atiq, Nicholas Simon, et al.
BMJ Oncology
|
August 1, 2024
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis
Elias B A Chandran, Giovanni Maria Iannantuono, Saad O Atiq, et al.
Future Oncology (London, England)
|
June 23, 2025
A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationale
Andre R Kydd, Elias Chandran, Nicholas I Simon, et al.
Biorxiv : the Preprint Server for Biology
|
August 1, 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology
Sumit Mukherjee, Sumeet Patiyal, Lipika R Pal, et al.
Page
of 3